TG Therapeutics Inc (TGTX) - Gross Profit Ratio

The growth in Briumvi prescriptions is creating a steady cash flow, as this chart confirms: the gross margin level is currently locked in, and the value is holding at 82.70. The speed of the drug's rollout and merger potential are providing positive momentum for TG Therapeutics, Inc. (TGTX). However, intense competition from pharma behemoths and the risk of biosimilars pose a serious threat to the biotech's long-term survival.
Financial and market metric breakdowns for TG Pharma (TGTX)

Gross margin measures the share of profit after deducting direct production costs, allowing investors to assess pricing efficiency and the business's ability to offset rising expenses. An analysis of the gross profit margin confirms that the commercial success of TG Therapeutics, Inc. (TGTX) drugs in neurology and oncology creates a sustainable cash flow driven by inelastic demand and economies of scale.